Is Kamada well-positioned for December economic uncertainties?

As many baby boomers are still indifferent towards healthcare space, it makes sense to go over Kamada. We will evaluate why we are still confident in anticipation of a recovery. Is the firm valuation justified? Here I will cover 2020 perspective on the current valuation of Kamada to give you a better outlook on taking a possible position in this stock.
Published over a year ago
View all stories for Kamada | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Rifka Kats

This firm currently holds 5.19 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest Kamada is not taking enough advantage from borrowing. The company has a current ratio of 5.67, suggesting that it is liquid enough and is able to pay its financial obligations when due. Kamada is UNDERVALUED at 8.49 per share with modest projections ahead.
We determine the current worth of Kamada using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kamada based exclusively on its fundamental and basic technical indicators. By analyzing Kamada's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Kamada's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kamada. We calculate exposure to Kamada's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kamada's related companies.

Kamada Investment Alerts

Kamada investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Kamada performance across your portfolios.Please check all investment alerts for Kamada

Kamada Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Kamada value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kamada competition to find correlations between indicators driving the intrinsic value of Kamada.

Is Kamada valued fairly by the market?

Kamada reported the previous year's revenue of 131.52 M. Net Income was 19.86 M with profit before overhead, payroll, taxes, and interest of 49.74 M.

Margins Breakdown

Kamada profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Kamada itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Kamada profit margins.
0.19
Profit Margin
0.24
EBITDA Margin
EBITDA Margin0.24
Gross Margin0.37
Profit Margin0.19
Kamada Average Assets is increasing over the last 8 years. Moreover, Kamada Earnings Before Interest Taxes and Depreciation Amortization EBITDA is somewhat stable at the moment.

Will Kamada price slip impact its balance sheet?

Current maximum drawdown is at 24.65. Kamada exhibits very low volatility with skewness of 1.11 and kurtosis of 3.15. However, we advise investors to further study Kamada technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Kamada

Whereas some other entities in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Kamada may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 11th of November 2020, our analysis shows that Kamada moves indifferently to market moves. The company is undervalued and projects very low chance of financial distress for the next 2 years. Our primary 30 days buy-or-sell advice on the company is Hold.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Kamada. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com